{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Rationale:', '-', 'To avoid confusion and make it clear that patients should be monitored after home', 'administration of IMP.', 'Country list/Region', 'In section: 11.1', 'Rationale:', '-', 'New Zealand is not a part of the study and should be removed.', 'Template', 'In section: Appendix K', 'Rationale:', '-', 'Instructions from the protocol template, which should be removed were left in the final', 'version of the protocol in error.', '-', 'Added clarification of PK sample blood volume for pediatric study.', 'Vaccination Response', 'In section: 10.1.2', 'Rationale:', '-', 'Vaccination information and vaccination plan during the treatment period should be', 'collected for all patients at screening, because the vaccination response is not an', 'optional assessment.', 'Adverse Event of Special Interest', 'In section: 10.4.1.3', 'Rationale:', '-', 'An error was noted in the asthma pediatric study EFC14153 study where \"suicidal', 'behavior\" was noted as AESI. Suicidal behavior was an AESI for atopic dermatitis', '(AD) trials; however, there was no signal of these events in patients treated with', 'dupilumab. Therefore, suicidal behavior was removed from the AESI.', 'Property of the Sanofi Group - strictly confidential', 'Page 181', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Term \"Slum areas\\'', 'In section: 10.6.3', 'Rationale:', '-', 'An alternative terminology, \"heavily populated informal settlements\" will be used for', 'the term \"slum areas\\'', 'Typographical Errors', 'In section: 1.1 (Overview of Study Design) schematic picture', 'Rationale:', '-', \"To correct a typographical error in subject number '195' (correct number '196') in the\", 'schematic picture of the overall study design in the original final protocol.', '-', 'To add footnote about background therapy with inhaled corticosteroids.', 'In section: 1.2 (Study flowchart) footnote U', 'Rationale:', '-', \"Although correctly found in the study flowchart at Week 6, in footnote 'U' it is written\", 'that DNA sampling collection is to be performed at Week 0.', '-', 'Blood DNA can be collected any time during the protocol, taking into consideration', 'blood collection volume limitation, if any, at the time.', 'In section: 7.2.3', 'Rationale:', '-', 'Deleted E23 (about previous history of malignancy), because it is a duplicate of E6', '(about history of malignancy).', '-', 'Clarified E25 Liver injury related criteria', '-', 'Corrected E26 Abnormal lab values at Screening', 'In addition, other minor changes were implemented.', 'Property of the Sanofi Group - strictly confidential', 'Page 182', 'VV-CLIN-0528583 6.0']['Signature Page for VV-CLIN-0528583 v6.0', 'efc14153-16-1-1-amended-protocol03', 'Approve & eSign', 'Approve & eSign', 'VV-CLIN-0528583 6.(']\n\n###\n\n", "completion": "END"}